Methylphenidate extended-release orally disintegrating tablets (Cotempla XR-ODT™) in attention-deficit hyperactivity disorder in children aged 6‒17 years: a profile of their use

Katherine A. Williamson
Compliance with ethical standards
Funding: The preparation of this review was not supported by any external funding.
Conflicts of interest: K.A. Lyseng-Williamson is a employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.
Additional information about this Adis Drug Review can be found here.
Abstract
The extended-release orally disintegrating tablet (XR-ODT) formulation of methylphenidate (Cotempla XR-ODT™) is an effective and generally well-tolerated option for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.